A Study of LY3374849 in Healthy Participants
Summary
The aim of this trial is to evaluate the safety and tolerability of the study drug known as LY3374849, when given as an injection to healthy participants. The study will also investigate how quickly the body absorbs and gets rid of LY3374849 and how it affects the levels of blood sugar in comparison to insulin degludec, after a single dose is given by injection under the skin and directly into a vein. Participation in this study includes screening, which is required within 28 days before start of study and a follow up at least 28 days after receiving the last dose of study drug. This study has 3 parts: * Participants in Part A will complete 1 study period (approximately 1 week). * Participants in Part B will complete 3 study periods (approximately 3 weeks). * Participants in Part C will complete 2 study periods (approximately 2 weeks).
Timeline
- Start
- 2018-11-20
- Primary completion
- 2019-09-27
- Completion
- 2019-09-27
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | LY3374849 | Unknown | — | Subcutaneous |
| Subject | insulin degludec | Protein / enzyme biologic | — | Subcutaneous |
Indications
No indication recorded.